Bladder cancer is the most frequent among the urothelial tumors, and it is responsible for about 2% of all cancer mortality worldwide. The mainstay of chemotherapy treatment, both for muscle-invasive and metastatic disease, is cisplatin-based regimens. In recent years, ground-breaking results have been achieved with immunotherapy, which have led to important breakthroughs in the bladder cancer treatment scenario, with the approval of several new agents. New insights derive from a greater characterization of the tumor genome, which could lead to developing new therapies, more personalized, in the near future.
GakisGEfstathiouJLernerSPInternational Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol2013; 63(1): 45-57
7.
HautmannREGschwendJEde PetriconiRCCystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol2006176D2486-492discussion 491-492.
8.
SherifARintalaEMestadONordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer Nordic cystectomy trial 2. Scand J Urol Nephrol2002; 36(6): 419-425
9.
GriffithsGHallRSylvesterRClub Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol2011; 29(16): 2171-2177
10.
GrossmanHBNataleRBTangenCMNeoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003; 349(9): 859-866
Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet20033611927-1934
13.
ValeCLAdvanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol2005; 48(2): 202-205discussion 205-206.
14.
GalskyMDPalSKChowdhurySRetrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer2015; 121(15): 2586-2593
15.
SternbergCNde MulderPHvan OosteromATFossaSDGiannarelliDSoedirmanJREscalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. Ann Oncol1993; 4(5): 403-407
16.
van dePutte EEFMertensLSMeijerRPNeoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J Urol2016; 34(2): 157-162
17.
PlimackERHoffman-CensitsJHViterboRAccelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol2014; 32(18): 1895-1901
18.
ChoueiriTKJacobusSBellmuntJNeoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol2014; 32(18): 1889-189432.
SchiffmannJSunMGandagliaGSuboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. Can Urol Assoc J2016; 10: 3-4E82-E86
21.
ZaidHBPatelSGStimsonCJTrends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology2014; 83(1): 75-80
22.
Di TrapaniESanchez SalasRGandagliaGA nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum based chemotherapy. World J Urol2015
23.
Leibowitz-AmitRIsraelAGalMAssociation between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer. Clin Oncol (R Coll Radiol)2016; 28(12): 790-796
24.
BarasASDrakeCLiuJJThe ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. OncoImmunology2016; 5(5):e1134412.
25.
GandhiNMBarasAMunariEGemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol2015; 33(5): 204e1-204.e7.
26.
BarasASGandhiNMunariEIdentification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma. PLoS ONE2015; 10(7):e0131245.
27.
DonatSMShabsighASavageCPotential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol2009; 55(1): 177-185
28.
LogothetisCJJohnsonDEChongCAdjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update. J Clin Oncol1988; 6(10): 1590-1596
29.
SkinnerDGDanielsJRRussellCAThe role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol1991; 145(3): 459-464discussion 464-467.
30.
StöckleMMeyenburgWWellekSAdvanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol1992; 148: 2 Pt 1302-306discussion 306-307.
31.
StöckleMMeyenburgWWellekSAdjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol1995; 153(1): 47-52
32.
StuderUEBacchiMBiedermannCAdjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol1994; 152(1): 81-84
33.
BonoAVBenvenutiCGibbaAAdjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol. Ital1997;11: 5-8
34.
FreihaFReeseJTortiFMA randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol1996; 155(2): 495-499discussion 499-500.
35.
OttoTBörgemannCKregeSAdjuvant chemotherapy in locally advanced bladder cancer (PT3/PN1-2, M0)—A Phase III Study. Eur Urol2001;39: 147
36.
Paz-AresLSolsonaEEstebanERandomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PCG) to observation in patients with resected invasive bladder cancer: Results of the SOGUG (Spanish Oncology Genito Urinary Group Study) 99/01 study. J Clin Oncol2010; 28: 18s(suppl; abstr LBA4518).
37.
CognettiFRuggeriEMFeliciAStudy Group. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol2012; 23(3): 695-700
38.
SternbergCNSkonecznaIKerstJMEuropean Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol2015; 16(1): 76-86
39.
SylvesterRSternbergCThe role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol2000; 11(7): 851-856
40.
ValeCLAdvanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol2005; 48(2): 189-199discussion 199-201.
41.
LeowJJMartin-DoyleWRajagopalPSAdjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol2014; 66(1): 42-54
42.
GalskyMDStenslandKDMoshierEEffectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol2016; 34(8): 825-832
43.
LoehrerPJSrEinhornLHElsonPJA randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol1992; 10(7): 1066-1073
44.
LogothetisCJDexeusFHFinnLA prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol1990; 8(6): 1050-1055
45.
SternbergCNde MulderPHMSchornagelJHEuropean Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol2001; 19(10): 2638-2646
46.
SternbergCNde MulderPSchornagelJHSeven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors (EORTC protocol 30924). Eur J Cancer2006; 42(1): 50-549.
47.
von derMaase HHansenSWRobertsJTGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol2000; 18(17): 3068-3077
48.
von derMaase HSengelovLRobertsJTLong-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol2005; 23(21): 4602-4608
49.
BellmuntJGuillemVPaz-AresLSpanish Oncology Genitourinary Group. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol2000; 18(18): 3247-3255
50.
BellmuntJvon derMaase HMeadGMRandomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol2012; 30(10): 1107-1113
51.
SternbergCNCalabròFPizzocaroGMariniLSchnetzerSSellaAChemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer2001; 92(12): 2993-2998
52.
GuardinoAESrinivasSGemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies [abstract]. Proc Am Soc Clin Oncol200221. Abstract 2413.
53.
FechnerGSienerRReimannMKobalzLAlbersPGerman Association Of Urologic Oncology (Auo) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract2006; 60(1): 27-31
54.
KaufmanDSCarducciMAKuzelTMA multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol2004; 22(5): 393-397
55.
MeluchAAGrecoFABurrisHAIII,Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol2001; 19(12): 3018-3024
56.
LiJJuliarBYiannoutsosCWeekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol2005; 23(6): 1185-1191
57.
CalabròFLorussoVRosatiGGemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer2009; 115(12): 2652-2659
58.
ShannonCCrombieCBrooksALauHDrummondMGurneyHCarboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol2001; 12(7): 947-952
59.
PetrioliRFredianiBManganelliAComparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer1996; 77(2): 344-351
60.
BellmuntJRibasAEresNCarboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer1997; 80(10): 1966-1972
61.
CarteniGDogliottiLCrucittaEPhase II randomised trial of gemcitabine plus cisplatin (GP) and gemcitabine plus carboplatin (GC) in patients (pts) with advanced or metastatic transitional cell carcinoma of the urothelium (TCCU). Proc ASCO2003;22: 384(Abstr 1543).
62.
GalskyMDHahnNMRosenbergJA consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol2011; 12(3): 211-214
63.
De SantisMBellmuntJMeadGRandomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol2012; 30(2): 191-199
64.
BellmuntJThéodoreCDemkovTPhase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol2009; 27(27): 4454-4461
65.
BellmuntJFougerayRRosenbergJELong-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol2013; 24(6): 1466-1472
66.
HarshmanLCFougerayRChoueiriTKThe impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. Br J Cancer2013; 109(10): 2548-2553
67.
SternbergCNCalabròFPizzocaroGMariniLSchnetzerSSellaAChemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer2001; 92(12): 2993-2998
68.
FechnerGSienerRReimannMKobalzLAlbersPGerman Association Of Urologic Oncology (Auo) Bladder Cancer Study Group. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract2006; 60(1): 27-31
69.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature2014; 507(7492): 315-322
70.
TopalianSLTaubeJMAndersRAPardollDMMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer2016; 16(5): 275-287
71.
RizviNAHellmannMDSnyderACancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science2015; 348(6230): 124-128
72.
SnyderAMakarovVMerghoubTGenetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med2014; 371(23): 2189-2199
73.
Van AllenEMMiaoDSchillingBGenomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science2015; 350(6257): 207-211
74.
RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet2016; 387(10031): 1909-1920
75.
DreicerRUpdated efficacy and >1-y follow up from IMvigor210: atezolizumab (atezo) in platinum (plat) treated locally advanced/metastatic urothelial carcinoma (m UC). ASCO Meet Abstr2016; 34: Suppl. 154515.
76.
BalarAVGalskyMDRosenbergJEIMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet2017; 389(10064): 67-76
77.
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]. ClinicalTrials.gov Identifier: NCT02302807.
78.
ZibelmanMUrologic Oncology. Seminars and Original Investigations2016;34: 538-547
79.
MassardCGordonMSSharmaSSafety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer, JCO2016
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor). ClinicalTrials.gov Identifier: NCT01772004.
82.
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100). ClinicalTrials.gov Identifier: NCT02603432.
83.
PlimackERBellmuntJGuptaSSafety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol2017; 18(2): 212-220
84.
BellmuntJde WitRVaughnDJKEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med2017; 376(11): 1015-1026
85.
BalarABellmuntJO'DonnellPHPembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study. Ann Oncol2016; 27(6): 1-36
CarthonBCWolchokJDYuanJPreoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res2010; 16(10): 2861-2871
90.
GalskyMDHahnNMAlbanyCPhase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.;J Clin Oncol 34, 2016suppl 2S; abstr 3572016 Genitourinary Cancers Symposium; NCT01524991.
91.
Morales-BarreraRSuárezCde CastroAMTargeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treat Rev2016;50: 208-216
92.
LernerSPKwiatkowskiWJUpdate on The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. Eur Urol Focus(2015)
93.
WeinsteinJNAkbaniRBroomBMCancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature2014; 507(7492): 315-322
